Trials
5 active
27 in total
Targets
—
None known yet
What this is
- How it works
- Norepinephrine, dopamine and serotonin reuptake inhibitor
- Tested for
- Attention-Deficit Hyperactivity Disorder(ADHD) (2 trials), Attention Deficit Hyperactivity Disorder (ADHD) (2 trials), Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
- Main trialPhase 3
- “The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).”In the company’s words, NCT07759154 on ClinicalTrials.gov
- Other names
- EB-1020 · Simtriyo
Other drugs for Attention-Deficit Hyperactivity Disorder(ADHD)
- AK-D101Alvogen Korea · Phase 3
- SolriamfetolAxsome Therapeutics, Inc. · Phase 3
- ALKS 7290Alkermes, Inc. · Phase 2
- SPN-812Supernus Pharmaceuticals, Inc. · Marketed (Phase 4 trial)
Coming up5
- 27 May 2027Phase 3 trial completes · ClinicalTrials.gov
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- Aug 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials27
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 27 May 2027 | A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | |
| Phase 3Recruiting | Aug 2027 | A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | |
| Phase 3Recruiting | Dec 2027 | A Long-term Trial of EB-1020 in Adult Patients With ADHD | |
| Phase 2/3Recruiting | Aug 2027 | A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | |
| Phase 2/3Recruiting | Dec 2027 | Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients | |
| Phase 3Completed | 11 Apr 2020 | A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder | |
| Phase 3Completed | 14 May 2020 | A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder | |
| Phase 3Completed | 7 Sep 2021 | A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder | |
| Phase 3Completed | 29 Sep 2023 | A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder | |
| Phase 3Completed | 17 Mar 2025 | A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD) | |
| Phase 3Completed | 22 Apr 2026 | P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety | |
| Phase 3Completed | 24 Apr 2026 | A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder. | |
| Phase 2Completed | 20 Feb 2014 | Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder | |
| Phase 2Completed | 4 Jun 2016 | Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) | |
| Phase 2Completed | 21 Dec 2019 | Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD) | |
| Phase 2Completed | 31 May 2022 | Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment | |
| Phase 2Completed | 19 Aug 2022 | A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder | |
| Phase 2Completed | 16 May 2025 | Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder | |
| Phase 1Completed | 1 Feb 2014 | A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 | |
| Phase 1Completed | 1 Jul 2014 | A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users | |
| Phase 1Terminated | Jan 2016 | A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects | |
| Phase 1Completed | 1 Apr 2021 | A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder | |
| Phase 1Completed | 26 Mar 2023 | A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine | |
| Phase 1Completed | 26 Apr 2023 | A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder | |
| Phase 1Completed | 18 May 2023 | Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects | |
| Phase 1Completed | 30 Dec 2024 | A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels | |
| Phase 1Completed | 30 Mar 2026 | A Trial to Assess How Centanafadine Interacts With Stimulants in the Body |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026